{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:02:43Z","timestamp":1787166163739,"version":"build-2736575974"},"reference-count":33,"publisher":"Walter de Gruyter GmbH","issue":"3","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,9,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_raon-2018-0030_s_001_w2aab2b8b5b1b7b1aab1c16b1Aa\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The aim of the study was to analyze the overall survival (OS) and progression free survival (PFS) of patients with high grade and advanced stage epithelial ovarian cancer (EOC) with at least 60 months of follow-up treated in a single gynecologic oncology institute. We compared primary debulking surgery (PDS) versus neoadjuvant chemotherapy plus interval debulking surgery (NACT + IDS) stratifying data based on residual disease with the intent to identify the rationale for therapeutic option decision and the role of laparoscopic evaluation of resectability for that intention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_raon-2018-0030_s_002_w2aab2b8b5b1b7b1aab1c16b2Aa\">\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>This is observational retrospective study on consecutive patients with diagnosis of high grade and International Federation of Gynecology and Obstetrics (FIGO) stage III\/IV EOC referred to our center between January 2008 and May 2012. We selected only patients with a follow-up of at least 60 months. Primary endpoint was to compare PDS versus NACT + IDS in term of progression free survival (PFS) and overall survival (OS). Secondary endpoints were PFS and OS stratifying data according to residual disease after surgery in patients receiving PDS versus NACT + IDS. Finally, through Cox hazards models, we tested the prognostic value of different variables (patient age at diagnosis, residual disease after debulking, American Society of Anesthesiologists (ASA) stage, number of adjuvant-chemotherapy cycles) for predicting OS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_raon-2018-0030_s_003_w2aab2b8b5b1b7b1aab1c16b3Aa\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total number of 157 patients were included in data analysis. Comparing PDS arm (108 patients) and NACT + IDS arm (49 patients) we found no significant differences in term of OS (41.3 versus 34.5 months, respectively) and PFS (17.3 versus 18.3 months, respectively). According to residual disease we found no significant differences in term of OS between NACT + IDS patients with residual disease = 0 and PDS patients with residual disease = 0 or residual disease = 1, as well as no significant differences in PFS were found comparing NACT + IDS patients with residual disease = 0 and PDS patients with residual disease = 0; contrarily, median PFS resulted significantly lower in PDS patients receiving optimal debulking (residual disease = 1) in comparison to NACT + IDS patients receiving complete debulking (residual disease = 0). PDS arm was affected by a significant higher rate of severe post-operative complications (grade 3 and 4). Diagnostic laparoscopy before surgery was significantly associated with complete debulking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_raon-2018-0030_s_004_w2aab2b8b5b1b7b1aab1c16b4Aa\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We confirm previous findings concerning the non-superiority of NACT + IDS compared to PDS for the treatment of EOC, even if NACT + IDS treatment was associated with significant lower rate of post-operative complications. On the other hand, selecting patients for NACT + IDS, based on laparoscopic evaluation of resectabilty prolongs the PFS and does not worse the OS compared to the patients not completely debulked with PDS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2478\/raon-2018-0030","type":"journal-article","created":{"date-parts":[[2018,9,13]],"date-time":"2018-09-13T05:30:53Z","timestamp":1536816653000},"page":"307-319","source":"Crossref","is-referenced-by-count":53,"title":["Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals"],"prefix":"10.2478","volume":"52","author":[{"given":"Borut","family":"Kobal","sequence":"first","affiliation":[{"name":"Division of Gynaecology and Obstetrics , University Medical Centre Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Noventa","sequence":"additional","affiliation":[{"name":"Department of Woman and Child Health , University of Padua , Padua , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branko","family":"Cvjeticanin","sequence":"additional","affiliation":[{"name":"Division of Gynaecology and Obstetrics , University Medical Centre Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matija","family":"Barbic","sequence":"additional","affiliation":[{"name":"Division of Gynaecology and Obstetrics , University Medical Centre Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon","family":"Meglic","sequence":"additional","affiliation":[{"name":"Division of Gynaecology and Obstetrics , University Medical Centre Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marusa","family":"Herzog","sequence":"additional","affiliation":[{"name":"Division of Gynaecology and Obstetrics , University Medical Centre Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Bordi","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics , University of Insubria , Varese , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amerigo","family":"Vitagliano","sequence":"additional","affiliation":[{"name":"Department of Woman and Child Health , University of Padua , Padua , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Saccardi","sequence":"additional","affiliation":[{"name":"Department of Woman and Child Health , University of Padua , Padua , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"M.D., Ph.D","given":"Erik","family":"Skof","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology , Institute of Oncology Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2018,9,11]]},"reference":[{"key":"2026071214185348167_j_raon-2018-0030_ref_001_w2aab2b8b5b1b7b1ab2ab1Aa","doi-asserted-by":"crossref","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017; 67: 7-30. 10.3322\/caac.21387","DOI":"10.3322\/caac.21387"},{"key":"2026071214185348167_j_raon-2018-0030_ref_002_w2aab2b8b5b1b7b1ab2ab2Aa","doi-asserted-by":"crossref","unstructured":"Ataseven B, Chiva LM, Harter P, Gonzalez-Martin A, du Bois A. FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisited. Gynecol Oncol 2016; 142: 597-607. 10.1016\/j.ygyno.2016.06.013","DOI":"10.1016\/j.ygyno.2016.06.013"},{"key":"2026071214185348167_j_raon-2018-0030_ref_003_w2aab2b8b5b1b7b1ab2ab3Aa","doi-asserted-by":"crossref","unstructured":"Kumar L, Pramanik R, Kumar S, Bhatla N, Malik S. Neoadjuvant chemotherapy in gynaecological cancers - Implications for staging. Best Pract Res Clin Obstet Gynaecol 2015; 29: 790-801. 10.1016\/j.bpobgyn.2015.02.008","DOI":"10.1016\/j.bpobgyn.2015.02.008"},{"key":"2026071214185348167_j_raon-2018-0030_ref_004_w2aab2b8b5b1b7b1ab2ab4Aa","doi-asserted-by":"crossref","unstructured":"du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe \u010fInvestigateurs Nationaux Pour les Etudes des Cancers de \u013eOvaire (GINECO). Cancer 2009 15; 115: 1234-44. 10.1002\/cncr.24149","DOI":"10.1002\/cncr.24149"},{"key":"2026071214185348167_j_raon-2018-0030_ref_005_w2aab2b8b5b1b7b1ab2ab5Aa","doi-asserted-by":"crossref","unstructured":"Kessous R, Laskov I, Abitbol J, Bitharas J, Yasmeen A, Salvador S, et al. Clinical outcome of neoadjuvant chemotherapy for advanced ovarian cancer. Gynecol Oncol 2017; 144: 474-9. 10.1016\/j.ygyno.2016.12.017","DOI":"10.1016\/j.ygyno.2016.12.017"},{"key":"2026071214185348167_j_raon-2018-0030_ref_006_w2aab2b8b5b1b7b1ab2ab6Aa","doi-asserted-by":"crossref","unstructured":"Liu Z, Beach JA, Agadjanian H, Jia D, Aspuria PJ, Karlan BY, et al. Suboptimal cytoreduction in ovarian carcinoma is associated with molecular pathways characteristic of increased stromal activation. Gynecol Oncol 2015; 139: 394-400. 10.1016\/j.ygyno.2015.08.026","DOI":"10.1016\/j.ygyno.2015.08.026"},{"key":"2026071214185348167_j_raon-2018-0030_ref_007_w2aab2b8b5b1b7b1ab2ab7Aa","doi-asserted-by":"crossref","unstructured":"G\u00f3mez-Hidalgo NR, Martinez-Cannon BA, Nick AM, Lu KH, Sood AK, Coleman RL, et al. Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care. Gynecol Oncol 2015; 137: 553-8. 10.1016\/j.ygyno.2015.03.049","DOI":"10.1016\/j.ygyno.2015.03.049"},{"key":"2026071214185348167_j_raon-2018-0030_ref_008_w2aab2b8b5b1b7b1ab2ab8Aa","doi-asserted-by":"crossref","unstructured":"Melamed A, Hinchcliff EM, Clemmer JT, Bregar AJ, Uppal S, Bostock I, et al. Trends in the use of neoadjuvant chemotherapy for advanced ovarian cancer in the United States. Gynecol Oncol 2016; 143: 236-40. 10.1016\/j.ygyno.2016.09.002","DOI":"10.1016\/j.ygyno.2016.09.002"},{"key":"2026071214185348167_j_raon-2018-0030_ref_009_w2aab2b8b5b1b7b1ab2ab9Aa","doi-asserted-by":"crossref","unstructured":"May T, Comeau R, Sun P, Kotsopoulos J, Narod SA, Rosen B, et al. A Comparison of Survival Outcomes in Advanced Serous Ovarian Cancer Patients Treated With Primary Debulking Surgery Versus Neoadjuvant Chemotherapy. Int J Gynecol Cancer 2017; 27: 668-74. 10.1097\/IGC.0000000000000946","DOI":"10.1097\/IGC.0000000000000946"},{"key":"2026071214185348167_j_raon-2018-0030_ref_010_w2aab2b8b5b1b7b1ab2ac10Aa","doi-asserted-by":"crossref","unstructured":"Mueller JJ, Zhou QC, Iasonos A, O\u2019Cearbhaill RE, Alvi FA, El Haraki A, et al. Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center. Gynecol Oncol 2016; 140: 436-42. 10.1016\/j.ygyno.2016.01.008","DOI":"10.1016\/j.ygyno.2016.01.008"},{"key":"2026071214185348167_j_raon-2018-0030_ref_011_w2aab2b8b5b1b7b1ab2ac11Aa","doi-asserted-by":"crossref","unstructured":"Rosen B, Laframboise S, Ferguson S, Dodge J, Bernardini M, Murphy J, et al. The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer. Gynecol Oncol 2014; 134: 462-7. 10.1016\/j.ygyno.2014.07.004","DOI":"10.1016\/j.ygyno.2014.07.004"},{"key":"2026071214185348167_j_raon-2018-0030_ref_012_w2aab2b8b5b1b7b1ab2ac12Aa","doi-asserted-by":"crossref","unstructured":"Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 2015; 386: 249-57. 10.1016\/S0140-6736(14)62223-6","DOI":"10.1016\/S0140-6736(14)62223-6"},{"key":"2026071214185348167_j_raon-2018-0030_ref_013_w2aab2b8b5b1b7b1ab2ac13Aa","doi-asserted-by":"crossref","unstructured":"Vergote I, Trop\u00e9 CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010; 363: 943-53. 10.1056\/NEJMoa0908806","DOI":"10.1056\/NEJMoa0908806"},{"key":"2026071214185348167_j_raon-2018-0030_ref_014_w2aab2b8b5b1b7b1ab2ac14Aa","doi-asserted-by":"crossref","unstructured":"Mahner S, Trillsch F, Chi D, Harter P, Pfisterer J, Hilpert F, et al. Neoadjuvant chemotherapy in ovarian cancer revisited. Ann Oncol 2016; 27 (Suppl 1): i30-2. 10.1093\/annonc\/mdw092","DOI":"10.1093\/annonc\/mdw092"},{"key":"2026071214185348167_j_raon-2018-0030_ref_015_w2aab2b8b5b1b7b1ab2ac15Aa","doi-asserted-by":"crossref","unstructured":"Cornelis S, Van Calster B, Amant F, Leunen K, van der Zee AG, Vergote I. Role of neoadjuvant chemotherapy in the management of stage IIIC-IV ovarian cancer: survey results from the members of the European Society of Gynecological Oncology. Int J Gynecol Cancer 2012; 22: 407-16. 10.1097\/IGC.0b013e31823ea1d8","DOI":"10.1097\/IGC.0b013e31823ea1d8"},{"key":"2026071214185348167_j_raon-2018-0030_ref_016_w2aab2b8b5b1b7b1ab2ac16Aa","doi-asserted-by":"crossref","unstructured":"Dewdney SB, Rimel BJ, Reinhart AJ, Kizer NT, Brooks RA, Massad LS, et al. The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: survey results from members of the Society of Gynecologic Oncologists. Gynecol Oncol 2010; 119: 18-21. 10.1016\/j.ygyno.2010.06.021","DOI":"10.1016\/j.ygyno.2010.06.021"},{"key":"2026071214185348167_j_raon-2018-0030_ref_017_w2aab2b8b5b1b7b1ab2ac17Aa","doi-asserted-by":"crossref","unstructured":"Chan YM, Ng TY, Ngan HY, Wong LC. Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study. Gynecol Oncol 2003; 88: 9-16. 10.1006\/gyno.2002.6849","DOI":"10.1006\/gyno.2002.6849"},{"key":"2026071214185348167_j_raon-2018-0030_ref_018_w2aab2b8b5b1b7b1ab2ac18Aa","doi-asserted-by":"crossref","unstructured":"Greimel E, Kristensen GB, van der Burg ME, Coronado P, Rustin G, del Rio AS, et al. European Organization for Research and Treatment of Cancer - Gynaecological Cancer Group and NCIC Clinical Trials Group. Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy. Gynecol Oncol 2013; 131: 437-44. 10.1016\/j.ygyno.2013.08.014","DOI":"10.1016\/j.ygyno.2013.08.014"},{"key":"2026071214185348167_j_raon-2018-0030_ref_019_w2aab2b8b5b1b7b1ab2ac19Aa","doi-asserted-by":"crossref","unstructured":"Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 2009; 250: 187-96. 10.1097\/SLA.0b013e3181b13ca2","DOI":"10.1097\/SLA.0b013e3181b13ca2"},{"key":"2026071214185348167_j_raon-2018-0030_ref_020_w2aab2b8b5b1b7b1ab2ac20Aa","doi-asserted-by":"crossref","unstructured":"Karam A, Ledermann JA, Kim JW, Sehouli J, Lu K, Gourley C, et al. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions. Ann Oncol 2017; 28: 711-7. 10.1093\/annonc\/mdx011","DOI":"10.1093\/annonc\/mdx011"},{"key":"2026071214185348167_j_raon-2018-0030_ref_021_w2aab2b8b5b1b7b1ab2ac21Aa","doi-asserted-by":"crossref","unstructured":"Chang SJ, Hodeib M, Chang J, Bristow RE. Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. Gynecol Oncol 2013; 130: 493-8. 10.1016\/j.ygyno.2013.05.040","DOI":"10.1016\/j.ygyno.2013.05.040"},{"key":"2026071214185348167_j_raon-2018-0030_ref_022_w2aab2b8b5b1b7b1ab2ac22Aa","doi-asserted-by":"crossref","unstructured":"Brand AH. Ovarian cancer debulking surgery: a survey of practice in Australia and New Zealand. Int J Gynecol Cancer 2011; 21: 30-5. 10.1097\/IGC.0b013e318205fb4f","DOI":"10.1097\/IGC.0b013e318205fb4f"},{"key":"2026071214185348167_j_raon-2018-0030_ref_023_w2aab2b8b5b1b7b1ab2ac23Aa","doi-asserted-by":"crossref","unstructured":"Dahm-K\u00e4hler P, Palmqvist C, Staf C, Holmberg E, Johannesson L. Centralized primary care of advanced ovarian cancer improves complete cytoreduction and survival - A population-based cohort study. Gynecol Oncol 2016; 142: 211-6. 10.1016\/j.ygyno.2016.05.025","DOI":"10.1016\/j.ygyno.2016.05.025"},{"key":"2026071214185348167_j_raon-2018-0030_ref_024_w2aab2b8b5b1b7b1ab2ac24Aa","doi-asserted-by":"crossref","unstructured":"Rauh-Hain JA, Melamed A, Wright A, Gockley A, Clemmer JT, Schorge JO, et al. Overall Survival Following Neoadjuvant Chemotherapy vs Primary Cytoreductive Surgery in Women With Epithelial Ovarian Cancer: Analysis of the National Cancer Database. JAMA Oncol 2017; 3: 76-82. 10.1001\/jamaoncol.2016.4411","DOI":"10.1001\/jamaoncol.2016.4411"},{"key":"2026071214185348167_j_raon-2018-0030_ref_025_w2aab2b8b5b1b7b1ab2ac25Aa","doi-asserted-by":"crossref","unstructured":"Petrillo M, Ferrandina G, Fagotti A, Vizzielli G, Margariti PA, Pedone AL, et al. Timing and pattern of recurrence in ovarian cancer patients with high tumor dissemination treated with primary debulking surgery versus neoadjuvant chemotherapy. Ann Surg Oncol 2013; 20: 3955-60. 10.1245\/s10434-013-3091-6","DOI":"10.1245\/s10434-013-3091-6"},{"key":"2026071214185348167_j_raon-2018-0030_ref_026_w2aab2b8b5b1b7b1ab2ac26Aa","doi-asserted-by":"crossref","unstructured":"da Costa AA, Valadares CV, Baiocchi G, Mantoan H, Saito A, Sanches S, et al. Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and the Risk of Platinum Resistance in Epithelial Ovarian Cancer. Ann Surg Oncol 2015; 22 (Suppl 3): S971-8. 10.1245\/s10434-015-4623-z","DOI":"10.1245\/s10434-015-4623-z"},{"key":"2026071214185348167_j_raon-2018-0030_ref_027_w2aab2b8b5b1b7b1ab2ac27Aa","doi-asserted-by":"crossref","unstructured":"Cooke SL, Brenton JD. Evolution of platinum resistance in high-grade serous ovarian cancer. Lancet Oncol 2011; 12: 1169-74. 10.1016\/S1470-2045(11)70123-1","DOI":"10.1016\/S1470-2045(11)70123-1"},{"key":"2026071214185348167_j_raon-2018-0030_ref_028_w2aab2b8b5b1b7b1ab2ac28Aa","doi-asserted-by":"crossref","unstructured":"Bian C, Yao K, Li L, Yi T, Zhao X. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer. Arch Gynecol Obstet 2016; 293: 63-8. 10.1007\/s00404-015-3813-z","DOI":"10.1007\/s00404-015-3813-z"},{"key":"2026071214185348167_j_raon-2018-0030_ref_029_w2aab2b8b5b1b7b1ab2ac29Aa","doi-asserted-by":"crossref","unstructured":"Lim MC, Yoo HJ, Song YJ, Seo SS, Kang S, Kim SH, et al. Survival outcomes after extensive cytoreductive surgery and selective neoadjuvant chemotherapy according to institutional criteria in bulky stage IIIC and IV epithelial ovarian cancer. J Gynecol Oncol 2017; 28: e48. 10.3802\/jgo.2017.28.e48","DOI":"10.3802\/jgo.2017.28.e48"},{"key":"2026071214185348167_j_raon-2018-0030_ref_030_w2aab2b8b5b1b7b1ab2ac30Aa","doi-asserted-by":"crossref","unstructured":"Cress RD, Chen YS, Morris CR, Petersen M, Leiserowitz GS. Characteristics of long-term survivors of epithelial ovarian cancer. Obstet Gynecol 2015; 126: 491-7. 10.1097\/AOG.0000000000000981","DOI":"10.1097\/AOG.0000000000000981"},{"key":"2026071214185348167_j_raon-2018-0030_ref_031_w2aab2b8b5b1b7b1ab2ac31Aa","doi-asserted-by":"crossref","unstructured":"Brown J, Frumovitz M. Mucinous tumors of the ovary: current thoughts on diagnosis and management. Curr Oncol Rep 2014; 16: 389. 10.1007\/s11912-014-0389-x","DOI":"10.1007\/s11912-014-0389-x"},{"key":"2026071214185348167_j_raon-2018-0030_ref_032_w2aab2b8b5b1b7b1ab2ac32Aa","doi-asserted-by":"crossref","unstructured":"Marchetti C, Kristeleit R, McCormack M, Mould T, Olaitan A, Widschwendter M, et al. Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single institution retrospective review. Gynecol Oncol 2017; 144: 57-60. 10.1016\/j.ygyno.2016.11.001","DOI":"10.1016\/j.ygyno.2016.11.001"},{"key":"2026071214185348167_j_raon-2018-0030_ref_033_w2aab2b8b5b1b7b1ab2ac33Aa","doi-asserted-by":"crossref","unstructured":"Gill SE, McGree ME, Weaver AL, Cliby WA, Langstraat CL. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection. Gynecol Oncol 2017; 144: 266-73. 10.1016\/j.ygyno.2016.11.021","DOI":"10.1016\/j.ygyno.2016.11.021"}],"container-title":["Radiology and Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/content.sciendo.com\/view\/journals\/raon\/52\/3\/article-p307.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/raon-2018-0030","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T23:07:10Z","timestamp":1783897630000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/raon-2018-0030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,1]]},"references-count":33,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,9,11]]},"published-print":{"date-parts":[[2018,9,11]]}},"alternative-id":["10.2478\/raon-2018-0030"],"URL":"https:\/\/doi.org\/10.2478\/raon-2018-0030","relation":{},"ISSN":["1581-3207"],"issn-type":[{"value":"1581-3207","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,1]]}}}